CO5190667A1 - Composicion farmaceutica que contiene un compuesto de tramadol y un anticonvulsivo seleccionado de topiramato, 1,2-etanodiol-1-(2-clorofenil)-2-carbamato, gabapentina y lamotrigina - Google Patents

Composicion farmaceutica que contiene un compuesto de tramadol y un anticonvulsivo seleccionado de topiramato, 1,2-etanodiol-1-(2-clorofenil)-2-carbamato, gabapentina y lamotrigina

Info

Publication number
CO5190667A1
CO5190667A1 CO00062273A CO00062273A CO5190667A1 CO 5190667 A1 CO5190667 A1 CO 5190667A1 CO 00062273 A CO00062273 A CO 00062273A CO 00062273 A CO00062273 A CO 00062273A CO 5190667 A1 CO5190667 A1 CO 5190667A1
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
ethanodiol
gabapentine
convulsive
lamotrigine
Prior art date
Application number
CO00062273A
Other languages
English (en)
Spanish (es)
Inventor
Ellen E Codd
Rebeca P Martinez
Kathryn E Rogers
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of CO5190667A1 publication Critical patent/CO5190667A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO00062273A 1999-08-20 2000-08-18 Composicion farmaceutica que contiene un compuesto de tramadol y un anticonvulsivo seleccionado de topiramato, 1,2-etanodiol-1-(2-clorofenil)-2-carbamato, gabapentina y lamotrigina CO5190667A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15020199P 1999-08-20 1999-08-20
US09/634,904 US6562865B1 (en) 1999-08-20 2000-08-09 Composition comprising a tramadol material and an anticonvulsant drug

Publications (1)

Publication Number Publication Date
CO5190667A1 true CO5190667A1 (es) 2002-08-29

Family

ID=22533492

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00062273A CO5190667A1 (es) 1999-08-20 2000-08-18 Composicion farmaceutica que contiene un compuesto de tramadol y un anticonvulsivo seleccionado de topiramato, 1,2-etanodiol-1-(2-clorofenil)-2-carbamato, gabapentina y lamotrigina

Country Status (31)

Country Link
US (1) US6562865B1 (https=)
EP (1) EP1210118B1 (https=)
JP (1) JP4977297B2 (https=)
KR (1) KR100758609B1 (https=)
CN (1) CN1198651C (https=)
AR (1) AR032132A1 (https=)
AT (1) ATE284223T1 (https=)
AU (1) AU782759B2 (https=)
BG (1) BG65996B1 (https=)
BR (1) BRPI0013439B8 (https=)
CA (1) CA2381797C (https=)
CO (1) CO5190667A1 (https=)
CR (1) CR6593A (https=)
CZ (1) CZ2002524A3 (https=)
DE (1) DE60016602T2 (https=)
EA (1) EA006598B1 (https=)
ES (1) ES2234651T3 (https=)
HU (1) HUP0203198A3 (https=)
IL (2) IL148019A0 (https=)
MX (1) MXPA02001820A (https=)
MY (1) MY136985A (https=)
NO (1) NO332342B1 (https=)
NZ (1) NZ517106A (https=)
PL (1) PL213323B1 (https=)
PT (1) PT1210118E (https=)
SK (1) SK286621B6 (https=)
TR (1) TR200201067T2 (https=)
TW (1) TWI259769B (https=)
UA (1) UA75868C2 (https=)
WO (1) WO2001013904A2 (https=)
ZA (1) ZA200201403B (https=)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100243956B1 (ko) 1991-09-06 2000-03-02 랄프 알. 팔로 트라마돌 물질 및 아세트아미노펜을 포함하는 통증 치료용 약제학적 조성물
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
PL213323B1 (pl) 1999-08-20 2013-02-28 Ortho Mcneil Pharm Inc Kompozycja farmaceutyczna i jej zastosowanie
DE19940740A1 (de) * 1999-08-31 2001-03-01 Gruenenthal Gmbh Pharmazeutische Salze
DE10049483A1 (de) * 2000-09-29 2002-05-02 Gruenenthal Gmbh Substituierte 1-Aminobutan-3-ol-Derivate
JP2005512965A (ja) * 2001-09-24 2005-05-12 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 不穏四肢症候群および定期的四肢運動障害の処置に有用な抗痙攣誘導体
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
RU2004126093A (ru) * 2002-02-26 2005-04-10 Орто-Макнейл Фармасьютикал, Инк. (Us) Комбинированная терапия для лечения мигрени, включающая применение производных противосудорожных средств и средств от мигрени
AU2003213719A1 (en) 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
EP1364649A1 (en) * 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof
IL165383A0 (en) 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
EP1565193B1 (en) 2002-11-06 2013-04-24 Dana-Farber Cancer Institute, Inc. Compositions for treating cancer using proteasome inhibitor PS-341
PL377351A1 (pl) * 2002-12-13 2006-01-23 Cilag Ag Preparaty o kontrolowanym uwalnianiu zawierające tramadol i topiramat
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
KR101043789B1 (ko) * 2003-03-31 2011-06-27 (주)에이스딕시오 디지털 신호 처리를 이용한 전력 측정기 및 그 전력 측정 방법과 그 방법을 수행하는 프로그램을 기록한 컴퓨터로 읽을 수 있는 기록매체
US20090214426A1 (en) * 2004-05-19 2009-08-27 Laura Corradini Assay Method
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
DE602005008084D1 (de) * 2004-08-24 2008-08-21 Janssen Pharmaceutica Nv Als antikonvulsive mittel geeignete neue benzokondensierte heteroarylsulfamidderivate
MX2007004491A (es) * 2004-10-15 2007-08-08 Johnson & Johnson Compuestos de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos.
KR20080005429A (ko) * 2005-04-19 2008-01-11 알자 코포레이션 트라마돌 및 가바펜틴을 포함하는 물질의 배합물
KR20080012360A (ko) * 2005-05-20 2008-02-11 얀센 파마슈티카 엔.브이. 설파미드 유도체의 제조 방법
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection
AU2006308889A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
MXPA05011735A (es) * 2005-11-01 2007-04-30 Leopoldo Espinosa Abdala Composiciones farmaceuticas que comprenden combinaciones de analgesicos y anticonvulsivantes para el tratamiento del dolor agudo y cronico.
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191452A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain
EA200870556A1 (ru) * 2006-05-19 2009-06-30 Янссен Фармацевтика Н.В. Комбинированная терапия в лечении эпилепсии и родственных расстройств
US20070293476A1 (en) * 2006-05-19 2007-12-20 Smith-Swintosky Virginia L Co-therapy for the treatment of epilepsy and related disorders
WO2007144195A2 (en) * 2006-06-15 2007-12-21 Schwarz Pharma Ag Pharmaceutical composition with synergistic anticonvulsant effect
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
MX2009004552A (es) * 2006-10-27 2009-11-10 Janssen Pharmaceutica Nv Metodos de tratamiento de trastornos de comportamiento perturbador.
US8298576B2 (en) 2006-11-17 2012-10-30 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
MX2009003911A (es) * 2006-12-04 2009-05-28 Supernus Pharmaceuticals Inc Formulaciones de liberacion inmediata, mejoradas de topiramato.
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
US8356315B2 (en) * 2007-12-03 2013-01-15 Koncelik Jr Lawrence J Setting television default channel
EP2250148B1 (en) 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
ES2601852T3 (es) * 2008-01-25 2017-02-16 Xenoport, Inc. Forma cristalina de sales de calcio de ácidos (3S)-aminometil-5-metil-hexanoicos y métodos de uso
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
EA018567B1 (ru) 2008-06-23 2013-08-30 Янссен Фармацевтика Нв Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
KR101730924B1 (ko) * 2008-09-05 2017-04-27 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
AR077987A1 (es) 2009-08-28 2011-10-05 Gruenenthal Gmbh Combinacion farmaceutica que comprende 6-dimetilaminometil-1-(3-metoxifenil)-ciclohexano-1,3-diol o 6-dimetilaminometil-1-(3-hidroxifenil)-ciclohexano-1,3-diol y un antiepileptico
EP2383255A1 (en) 2010-04-28 2011-11-02 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
CA2805371C (en) 2010-07-30 2017-10-31 Toray Industries, Inc. Therapeutic agent or prophylactic agent for neuropathic pain
EP2530072A1 (en) 2011-06-03 2012-12-05 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
US10702485B2 (en) * 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
DE102013009114A1 (de) * 2013-05-29 2014-12-04 Franz Gerstheimer Pharmazeutische Zusammensetzung zur Überwindung von Metabolisierungsproblemen
WO2017118726A1 (en) 2016-01-06 2017-07-13 Lonza Ltd Inhibition of protein degradation for improved production
US11464756B1 (en) 2017-05-19 2022-10-11 Jerry Darm Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof
IL277402B1 (en) 2018-03-20 2026-04-01 Abraxis Bioscience Llc Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
WO2020044070A1 (es) 2018-08-30 2020-03-05 Grünenthal GmbH Combinación farmacéutica sinérgica que comprende tramadol clorhidrato y pregabalina, y su uso para el tratamiento del dolor neuropático
CN114096314A (zh) * 2019-06-27 2022-02-25 沼泽敏彦 痴呆症的治疗和预防药
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652589A (en) 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US3562589A (en) * 1968-09-09 1971-02-09 Ite Imperial Corp Electrically resetting undervoltage trip for circuit breakers
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4587252A (en) * 1984-12-18 1986-05-06 Brighton Pharmaceutical, Inc. Hydrocodone/ibuprofen pharmaceutical compositions and method
US4569937A (en) * 1985-02-11 1986-02-11 E. I. Du Pont De Nemours And Company Analgesic mixture of oxycodone and ibuprofen
CA2077637C (en) 1991-09-06 2007-01-09 Robert B. Raffa Compositions comprising a tramadol material and any of codeine, oxycodone or hydrocodone and their use
KR100243956B1 (ko) * 1991-09-06 2000-03-02 랄프 알. 팔로 트라마돌 물질 및 아세트아미노펜을 포함하는 통증 치료용 약제학적 조성물
US5516803A (en) 1991-10-30 1996-05-14 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
GB9417532D0 (en) 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
CZ297679B6 (cs) * 1996-08-14 2007-03-07 G. D. Searle & Co. Krystalická forma B 4-[5-methyl-3-fenylizoxazol-4-yl]benzensulfonamidu
WO1998007447A1 (en) * 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
EP1014959B1 (en) * 1997-08-15 2004-10-20 Carolyn Ann Fairbanks Agmatine as a treatment for neuropathic pain
JP3782935B2 (ja) * 1997-09-08 2006-06-07 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 抗癲癇化合物を含有する鎮痛剤組成物およびその使用方法
PL213323B1 (pl) 1999-08-20 2013-02-28 Ortho Mcneil Pharm Inc Kompozycja farmaceutyczna i jej zastosowanie

Also Published As

Publication number Publication date
WO2001013904A2 (en) 2001-03-01
HUP0203198A2 (hu) 2003-02-28
TR200201067T2 (tr) 2002-09-23
KR20020025221A (ko) 2002-04-03
US6562865B1 (en) 2003-05-13
ES2234651T3 (es) 2005-07-01
ATE284223T1 (de) 2004-12-15
MXPA02001820A (es) 2003-07-14
SK2262002A3 (en) 2003-02-04
BG65996B1 (bg) 2010-09-30
DE60016602D1 (de) 2005-01-13
BRPI0013439A (pt) 2002-04-30
EP1210118A2 (en) 2002-06-05
CR6593A (es) 2009-01-16
HUP0203198A3 (en) 2005-07-28
JP4977297B2 (ja) 2012-07-18
AU6895800A (en) 2001-03-19
BG106420A (bg) 2002-09-30
NO20020728D0 (no) 2002-02-13
UA75868C2 (en) 2006-06-15
TWI259769B (en) 2006-08-11
AR032132A1 (es) 2003-10-29
NZ517106A (en) 2005-04-29
KR100758609B1 (ko) 2007-09-13
MY136985A (en) 2008-12-31
AU782759B2 (en) 2005-08-25
PT1210118E (pt) 2005-02-28
IL148019A0 (en) 2002-09-12
EP1210118B1 (en) 2004-12-08
IL148019A (en) 2012-03-29
CA2381797A1 (en) 2001-03-01
WO2001013904A3 (en) 2001-06-14
PL353266A1 (en) 2003-11-03
CN1198651C (zh) 2005-04-27
EA200200183A1 (ru) 2002-08-29
DE60016602T2 (de) 2005-11-03
CN1379686A (zh) 2002-11-13
SK286621B6 (sk) 2009-02-05
JP2003507421A (ja) 2003-02-25
ZA200201403B (en) 2003-07-30
EA006598B1 (ru) 2006-02-24
BRPI0013439B8 (pt) 2021-07-06
NO20020728L (no) 2002-04-05
CA2381797C (en) 2008-04-15
CZ2002524A3 (cs) 2002-11-13
NO332342B1 (no) 2012-09-03
BRPI0013439B1 (pt) 2012-07-24
PL213323B1 (pl) 2013-02-28

Similar Documents

Publication Publication Date Title
CO5190667A1 (es) Composicion farmaceutica que contiene un compuesto de tramadol y un anticonvulsivo seleccionado de topiramato, 1,2-etanodiol-1-(2-clorofenil)-2-carbamato, gabapentina y lamotrigina
ES2109062T3 (es) Composiciones cosmeticas que contienen un compuesto lipidico de tipo ceramida y un peptido de una cadena grasa, y sus utilizaciones.
ID24929A (id) Turunan 2-aril-8-oksodihidropurin, proses pembuatannya, komposisi farmasinya yang mengandungnya, dan senyawa antaranya
ES2172092T3 (es) Asociacion de un retinoide con un polimero poliaminado.
ES2155874T3 (es) Composiciones cosmeticas que contienen acido betulinico.
PT747050E (pt) Composicoes farmaceuticas que contem irbesartan
ES2114487B1 (es) Mezcla estabilizante sinergistica.
DE19681668T1 (de) Hochfester Baggerzahn
ID25528A (id) Karboksamidotiazol tersubstitusi, pembuatannya dan komposisi farmasi yang mengandungnya
EP1011621A4 (en) METHOD AND COMPOSITIONS FOR WHITENING TEETH
CA2135575A1 (fr) Composition cosmetique contenant en tant qu'agent reducteur un n-mercapto-alkyl alcanediamide ou l'un de ses sels cosmetiquement acceptable
ES2173284T3 (es) Agentes endoparasicitidas.
AR021777A1 (es) UNA COMPOSICIoN PARA ACONDICIONAR, ACLARAR E ILUMINAR EL CABELLO Y UN MÉTODO PARA ACONDICIONAR, ACLARAR E ILUMINAR EL CABELLO.
ES2118393T3 (es) Posavaso quimiluminiscente.
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
AR013414A1 (es) Una composicion de dentifrico de dos componentes y el metodo para mejorar la remocion del crecimiento de placa y proporcionar una sensacion novedosa dehormigueo en la boca con dicha composicion.
ES2186009T3 (es) Dendrimeros de epoxi-amina y la preparacion y uso de los mismos.
ES2170143T3 (es) Composiciones que comprenden halofantrina en una forma especial.
BR9801507A (pt) Despolimerização de poliamidas.
ATE305517T1 (de) Neurotrypsin
ES2188894T3 (es) Lactonas macrociclicas perfumadas.
CU22820A3 (es) Mezcla de aminoácidos y su uso contra la micosis
ID26506A (id) Turunan-turunan n-fenilamida dan n-piridilamida, metode pembuatannya dan komposisi-komposisi farmasi yang mengandungnya
BR0112537A (pt) Preparações cosméticas de embelezamento contendo dialquilcarbonatos e óxidos de metal
PT1288203E (pt) Nitronas ciclicas e composicoes farmaceuticas que as contem

Legal Events

Date Code Title Description
FG Application granted